Celldex Therapeutics Inc.
NASDAQ:CLDX
| Market Cap (Intraday) | 1.73B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $39.47 |
| 50-Day MA | $43.71 |
| 200-Day MA | $35.52 |
Celldex Therapeutics Inc. Stock, NASDAQ:CLDX
Perryville III Building, 53 Frontage Road, Hampton, New Jersey 08827
United States of America
Phone: +1.908.454.7120
Number of Employees: 148
Description
Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.